See more : Yodogawa Steel Works, Ltd. (YDWAF) Income Statement Analysis – Financial Results
Complete financial analysis of Shenzhen YHLO Biotech Co., Ltd. (688575.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shenzhen YHLO Biotech Co., Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Prospa Group Limited (PGL.AX) Income Statement Analysis – Financial Results
- Fuud AB (publ) (FUUD.ST) Income Statement Analysis – Financial Results
- Cisen Pharmaceutical Co., Ltd. (603367.SS) Income Statement Analysis – Financial Results
- The Musashino Bank, Ltd. (8336.T) Income Statement Analysis – Financial Results
- YU-WA Creation Holdings Co.,Ltd. (7615.T) Income Statement Analysis – Financial Results
Shenzhen YHLO Biotech Co., Ltd. (688575.SS)
About Shenzhen YHLO Biotech Co., Ltd.
Shenzhen YHLO Biotech Co., Ltd. engages in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents in China. It offers clinical solutions for autoimmune, reproductive health, infectious, and other diseases; CLIA test panels, chemiluminescence immunoassay analyzers, and integration systems for immunoassay; ELISA test panels and immune analyzers; LIA test panels, blot analyzers, and line immunoassays; POCT test panels and immunofluorescence readers; ESR Analyzers; and COVID-19 detection kits. The company also exports its COVID-19 detection kits to various countries, including Germany, France, Italy, Denmark, Sweden, etc. Shenzhen YHLO Biotech Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.05B | 3.98B | 1.18B | 999.01M | 877.36M | 728.64M | 530.06M |
| Cost of Revenue | 886.81M | 1.83B | 508.33M | 397.96M | 432.67M | 440.19M | 335.90M |
| Gross Profit | 1.17B | 2.15B | 669.56M | 601.05M | 444.69M | 288.45M | 194.16M |
| Gross Profit Ratio | 56.81% | 53.97% | 56.84% | 60.16% | 50.68% | 39.59% | 36.63% |
| Research & Development | 317.18M | 240.31M | 130.74M | 103.18M | 81.50M | 53.22M | 41.41M |
| General & Administrative | -62.02M | 47.53M | 31.16M | 19.96M | 21.17M | 18.07M | 29.20M |
| Selling & Marketing | 221.61M | 493.03M | 216.15M | 179.83M | 154.87M | 124.67M | 87.29M |
| SG&A | 159.58M | 540.55M | 247.32M | 199.79M | 176.04M | 142.74M | 116.49M |
| Other Expenses | 348.98M | 93.97M | 39.50M | 20.56M | 34.07M | -446.09K | 95.79K |
| Operating Expenses | 825.75M | 874.84M | 417.56M | 323.52M | 291.61M | 224.71M | 177.27M |
| Cost & Expenses | 1.71B | 2.71B | 925.89M | 721.48M | 724.28M | 664.90M | 513.17M |
| Interest Income | 14.31M | 9.01M | 5.37M | 1.76M | 169.41K | 250.05K | 1.26M |
| Interest Expense | 7.51M | 8.41M | 11.22M | 13.17M | 17.57M | 4.89M | 1.54M |
| Depreciation & Amortization | 197.00M | 152.45M | 104.53M | 73.73M | 39.42M | 21.31M | 2.77M |
| EBITDA | 537.36M | 1.34B | 344.75M | 324.18M | 183.12M | 76.03M | 24.52M |
| EBITDA Ratio | 26.17% | 35.82% | 30.30% | 33.88% | 23.29% | 12.16% | 4.63% |
| Operating Income | 340.55M | 1.20B | 226.84M | 246.57M | 126.01M | 50.13M | 13.63M |
| Operating Income Ratio | 16.59% | 30.19% | 19.26% | 24.68% | 14.36% | 6.88% | 2.57% |
| Total Other Income/Expenses | -6.44M | -15.23M | 919.31K | -5.06M | -35.92K | -446.09K | 95.79K |
| Income Before Tax | 334.11M | 1.19B | 227.76M | 241.50M | 125.98M | 49.69M | 13.72M |
| Income Before Tax Ratio | 16.27% | 29.81% | 19.34% | 24.17% | 14.36% | 6.82% | 2.59% |
| Income Tax Expense | 54.91M | 164.97M | 23.91M | 33.54M | 19.90M | 11.65M | 7.83M |
| Net Income | 355.01M | 1.01B | 204.75M | 210.53M | 107.54M | 38.03M | 5.89M |
| Net Income Ratio | 17.29% | 25.43% | 17.38% | 21.07% | 12.26% | 5.22% | 1.11% |
| EPS | 0.62 | 1.79 | 0.36 | 0.37 | 0.19 | 0.08 | 0.01 |
| EPS Diluted | 0.62 | 1.78 | 0.36 | 0.37 | 0.19 | 0.08 | 0.01 |
| Weighted Avg Shares Out | 568.13M | 565.58M | 567.00M | 567.00M | 567.00M | 483.89M | 412.62M |
| Weighted Avg Shares Out (Dil) | 572.60M | 568.76M | 567.00M | 567.00M | 567.00M | 484.06M | 412.62M |
Source: https://incomestatements.info
Category: Stock Reports